Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle*5

Anja M. Swenson‡1, Wanjian Tang‡1, Cheavar A. Blair§1, Christopher M. Fetrow§, William C. Unrath§, Michael J. Previs‡5, Kenneth S. Campbell‡5, and Christopher M. Yengo‡1

From the ‡Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033; the §Department of Physiology and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536-0298, and the ‡Department of Molecular Physiology and Biophysics, Cardiovascular Research Institute, University of Vermont, Burlington, Vermont 05405

Edited by Velia M. Fowler

The small molecule drug omecamtiv mecarbil (OM) specifically targets cardiac muscle myosin and is known to enhance cardiac muscle performance, yet its impact on human cardiac myosin motor function is unclear. We expressed and purified human cardiac myosin and is known to enhance cardiac muscle myosin and is known to enhance cardiac muscle myosin and is known to enhance cardiac muscle myosin. We demonstrate that OM can reduce the actin sliding velocity more than 100-fold in the presence of OM, whereas the actin concentration required for half-maximal ATPase was reduced dramatically (30-fold). We find OM does not change the overall actin affinity. Transient kinetic experiments suggest that there are two kinetic pathways in the presence of OM. The dominant pathway results in a slow transition between actomyosin-ADP states and increases the time myosin is strongly bound to actin. However, OM also traps a population of myosin heads in a weak actin affinity state with slow product release. We demonstrate that OM can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay. The ionic strength dependence of in vitro motility suggests the inhibition may be at least partially due to drag forces from weakly attached myosin heads. OM causes an increase in duty ratio examined in the motility assay. Experiments with permeabilized human myocardium demonstrate that OM increases calcium sensitivity and slows force development (Kₚ) in a concentration-dependent manner, whereas the maximally activated force is unchanged. We propose that OM increases the myosin duty ratio, which results in enhanced calcium sensitivity but slower force development in human myocardium.

Heart failure continues to be a major health problem worldwide, and despite current treatment options, the 5-year mortality rate remains relatively high (42%) (1, 2). In systolic heart failure, inotropic drugs, including β-agonists and phosphodies- terase inhibitors, are utilized to enhance cardiac muscle contractile force in individuals that are hypokinetic (3). However, prolonged use of these drugs is associated with increased myocardial oxygen demand, arrhythmias, and impaired calcium signaling (4, 5). Recently, drugs are being pursued that directly interact with cardiac myosin, the molecular motor that drives contraction in the heart, to enhance contractile force without altering intracellular calcium concentrations (6).

Muscle contraction is driven by an ATP-dependent cyclic interaction between the myosin thick filaments and actin thin filaments, with contraction and relaxation dependent on calci- um-mediated changes in the thin filament regulatory proteins troponin/tropomyosin (7). Thick filament-associated proteins also play a role in regulating contraction (8, 9). A solid understanding of the conserved actomyosin ATPase pathway has emerged from decades of biochemical, biophysical, and structural studies (Scheme 1) (10, 11). ATP binding to actomyosin (Kₜₐ₈) dramatically weakens the affinity of myosin for actin and rapidly dissociates the complex, which allows for ATP hydrolysis to occur in a detached state (Kₚ₈). Thus, the M-ATP and M-ADP-Pₐ states are referred to as weak actin binding states (boldface in Scheme 1), and the M-ADP and nucleotide-free states are referred to as strong actin binding states. The binding of M-ADP-Pₐ to actin triggers the myosin power stroke that is followed by an essentially irreversible phosphate release step (Kₚ₈) (12, 13). A second power stroke is thought to occur after phosphate release but is controversial (before Kₚ₈) (12, 14). The release of ADP from the active site (Kₕ₈) is the step that limits detachment from actin and is thus thought to be the step that limits maximum shortening velocity in muscle (15). However, attachment-limited models have also been proposed that can explain maximum shortening velocity in the context of the myosin ATPase cycle (16, 17).

Omecamtiv mecarbil (OM)² is an allosteric modulator of human β-cardiac myosin that is currently in phase II clinical trials (18–20). OM was found to be specific for cardiac myosin.

*This work was supported by American Heart Association Grant 14GRNT20380068 and National Institutes of Health Grant R01HL127699 (to C. M. Y.), American Heart Association Grant 15GRNT25460003 and National Institutes of Health Grant UL1TR001117 (to K. S. C.), and National Institutes of Health Grant R00HL124041 (to M. J. P.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

1 This article contains supplemental Fig. S1.

To whom correspondence should be addressed: Dept. of Cellular and Molecular Physiology, Pennsylvania State College of Medicine, 500 University Dr., Hershey, PA 17033. Tel.: 717-531-8575; E-mail: cmy11@psu.edu.

‡1 The abbreviations used are: OM, omecamtiv mecarbil; mant, N-methylan- thraniloyl; ELC, essential light chain.

2 The abbreviations used are: OM, omecamtiv mecarbil; mant, N-methylan- thraniloyl; ELC, essential light chain.
and does not alter skeletal or smooth muscle myosin (6). Muscle fiber studies that have examined the impact of OM are somewhat contradictory. A study that utilized rat cardiac muscle found enhanced contractility (fractional shortening) without changes in the calcium transient (6). Other studies have revealed an increase in calcium sensitivity as measured by the force-PCa relationship in mouse and rat myocardium, but a slowing of force development and relaxation was also noted (21, 22). Only one study has examined human myocardium and found a slowing of cross-bridge kinetics and an increase in sensitivity to calcium (23).

To investigate how OM impacts cardiac muscle motor performance, studies have examined purified cardiac myosin using steady-state and transient kinetic analysis as well as in vitro motility assays (6, 24). A study on porcine cardiac myosin determined that OM alters the hydrolysis equilibrium constant to favor products and enhances the rate of actin-activated phosphate release, but it does not change the ADP release step (24). These factors were predicted to enhance the number of myosin cross-bridges in the bound state, which would explain the increased force in muscle fiber studies. However, OM was found to decrease the maximum actin-activated ATPase rate (~2-fold) (24), but the step(s) in the ATPase cycle slowed by OM were not determined. Interestingly, it was found that OM dramatically reduces (10–20-fold) the sliding velocity in the in vitro motility assay (24–27). These results were puzzling because the study by Liu et al. (24) found no change in the ADP release rate constant, and this step correlates with sliding velocity in a detachment limited model of actomyosin motility. Thus, it has been proposed that the increase in the number of actin-bound cross-bridges enhances the load experienced by the force generating cross-bridges and slows the ADP release rate constant and hence sliding velocity (24). The ADP release step has indeed been demonstrated to be load-sensitive and responsible for the load-dependent changes in the ATPase rate in contracting muscle (28, 29). Therefore, further investigation of specific step(s) in the ATPase cycle that are slowed by OM is required to define the complete kinetic mechanism. In addition, it is important to directly measure the duty ratio, the fraction of the ATPase cycle myosin is bound to actin, in the in vitro motility assay to evaluate hypotheses about how OM dramatically slows sliding velocity. Finally, it is important to examine the impact of OM on human cardiac myosin as well as human cardiac muscle to allow direct correlations to clinical studies.

In this study, we investigated the mechanism of action of OM on recombinant human β-cardiac myosin using steady-state and transient kinetic measurements as well as in vitro motility assays. We also studied the impact of the drug on the muscle mechanics of human myocardium. We find that OM dramatically alters the myosin ATPase kinetics, which creates enhanced drag forces that contribute to the slowing of sliding velocity. Based on measurements with permeabilized human cardiac muscle, we find that OM increases calcium sensitivity and slows force generation, but it does not change steady-state force at saturating calcium concentrations.

Results

Purification of M2β-S1—We obtained ~0.75–1.0 mg of M2β-S1 per 30 plates of infected C2C12 cells. The M2β-S1 was 95% pure based on Coomassie-stained SDS-polyacrylamide gels (Fig. 1). We assumed the two low molecular weight bands, which co-purified with the M2β-S1 heavy chain (99,021 kDa), corresponded to the myosin light chains. The low molecular weight bands were excised from the gel and digested into peptides using trypsin, and their sequences were determined using LC-MS/MS. The upper band generated unique peptides from two essential light chain isoforms as follows: nine peptides corresponding to 65% of the myosin light chain 1/3 (Myl1) sequence, skeletal muscle isoform (UniProt P05977), and 13 peptides corresponding to 55% of the myosin light chain 4 (Myl4) sequence, atrial/fetal isoform (UniProt P09541). The lower band generated 12 highly abundant unique peptides corresponding to 70% of the sequence of myosin regulatory light chain 2 (Mylp6), skeletal muscle isoform (UniProt P97457). The mouse essential light chains My11 and My14 were 75 and 79% identical and 83 and 91% similar, respectively, to the human cardiac muscle essential light chain (Myl3) (UniProt P08590). The mouse regulatory light chain contains 74% sequence identity and 87% sequence similarity with the human cardiac muscle regulatory light chain (Myl2) (UniProt P10916) (see supplemental Fig. S1 for alignments).

Actin-activated ATPase of M2β-S1—The maximum actin-activated ATPase rate and actin dependence of the ATPase rate of M2β-S1 were not significantly impacted by the presence of DMSO (0.1%) (Fig. 2A and Table 1). Biotinylation of the Avi tag of M2β-S1 also did not alter the ATPase activity. The presence of 10 μM OM reduced the maximal ATPase (kcat) 4.5-fold and dramatically reduced the actin concentration at which ATPase is half-maximal (KATPase) 30-fold. The OM-induced inhibition of the actin-activated ATPase was evaluated in a concentration-dependent manner to determine the EC50 (0.52 ± 0.10 μM) (Fig. 2B).

Actin Co-sedimentation Assays with M2β-S1—We examined the steady-state actin affinity of M2β-S1 using actin co-sedimentation assays (Fig. 2C). The experiments were performed using conditions nearly identical to the ATPase assays with the exception that the co-sedimentation assay was performed over a longer time period (~10 min). The actin-affinity of M2β-S1 in
the presence of ATP was similar in the presence and absence of OM ($K_{\text{actin}} = 145 \pm 18$ and $155 \pm 13$ µM, respectively).

**Transient Kinetic Analysis of Actin-activated Product Release**—We examined the ADP release rate constant by mixing the actomyosin-mantADP complex (0.5 µM M2β-S1, 0.6 µM actin, 10 µM mantADP) with saturating ATP (1 mM), and we found that there was no difference in the presence and absence of OM ($k_{\text{obs}} = 313 \pm 6$ and $306 \pm 5$ s⁻¹, respectively) (data not shown). We also performed single turnover sequential mix experiments in the stopped flow to monitor the actin-activated product release steps of M2β-S1 in the presence and absence of OM (Fig. 3). The experiment was performed by mixing M2β-S1 with substoichiometric mantATP, aging the reaction for 10 s to allow ATP binding and hydrolysis, and then mixing with varying concentrations of actin (0.25 µM M2β-S1, 0.23 µM mantATP, varying actin concentrations). We observed a two-exponential fluorescence transient at each actin concentration both in the presence and absence of OM (Fig. 3A–D). The rate constant of the slow phase was independent of actin concentration and relatively similar in the presence and absence of OM (0.1–0.6 s⁻¹). The fast phase was hyperbolically dependent on actin concentration, and the maximum rate saturated at a much lower actin concentration in the presence of OM. In addition, the maximum rate constant of the fast phase was reduced in the presence of OM (4.3 ± 0.5 s⁻¹) compared with the absence (11.2 ± 0.1 s⁻¹). The relative amplitudes of the fast and slow phases were dependent on actin concentration with the fast phase more pronounced at a higher actin concentration (Fig. 3C). At high actin concentrations (40 µM), the relative amplitude of the slow phase was increased in the presence of OM (30%) compared with the absence (10%). Thus, the presence of OM slows actin-activated product release by reducing the rate constant of the fast pathway and increasing the flux through the slower product release pathway.

**In Vitro Motility of M2β-S1**—The sliding velocity produced by M2β-S1 in the *in vitro* motility assay was evaluated in the presence of DMSO and 10 µM OM by examining three separate protein preparations at a loading concentration of 0.48 µM (Fig. 4). There were slight differences in the average sliding velocity (50 filaments) determined in each preparation for the DMSO (1646 ± 30, 1837 ± 36, and 1469 ± 22 nm/s) and OM (7.87 ± 0.14, 6.50 ± 0.22, and 6.23 ± 0.19 nm/s) conditions. Control experiments performed in the absence of ATP demonstrated no movement during a 10-min acquisition (data not shown), which confirmed the sensitivity of the velocity measurements. Therefore, the data from all three preparations was pooled together (150 filaments) to determine the average sliding velocity in the presence of DMSO (1651 ± 24 nm/s) or OM (6.87 ± 0.12 nm/s). The average velocity of M2β-S1 was similar in the
strated that the EC50 was 5-fold lower (0.10 
concentration-dependent inhibition of 
the slow pathway may stabilize the traditionally 
The difference in the degree of OM-induced inhibi-
tion in ATPase and 
attenuation of drag forces from weakly bound myosin heads.

Density Dependence of in Vitro Motility—We examined the 
density dependence of the sliding velocity by performing the in vitro motility assay as a function of M2β-S1 concentration loaded into the flow cell. At low ionic strength (MOPS20 buffer) in the absence of OM, we observed little change in the density dependence, but in the presence of OM, the velocity increased 2.5-fold as the loading concentration was decreased from 2.0 to 0.24 μM (Fig. 6, A and B). At higher ionic strength (100 mM KCl) in the absence of OM, the velocities gradually decreased as density was decreased, whereas in the presence of OM, the velocity increase at lower densities was attenuated compared with low ionic strength conditions.

Duty Ratio Measurements—To evaluate the hypothesis that OM increases the duty ratio, we attempted to directly examine the duty ratio in the in vitro motility assay (100 mM KCl) by examining the velocity as a function of available myosin heads on the surface (Fig. 7, A and B). We determined the number of heads on the motility surface using NH4-ATPase assays (38 heads and 117 heads per μM of actin filament at 0.24 and 0.35 μM loading concentrations, respectively). We found it difficult to obtain sliding velocities at low motor density (≤10 available heads), and thus fitting the data to established equations (33, 34) was not robust. We did observe a trend in the data that demonstrated a relative increase in duty ratio in the presence of OM compared with DMSO. We also evaluated the duty ratio by plotting the velocity as a function of actin filament length at 0.24 μM loading concentration, and a similar trend was observed (Fig. 7B).

Muscle Mechanics of Human Myocardium—To evaluate the effects of OM on the contractile properties of human myocardium, we performed experiments using chemically permeabilized multicellular preparations. Maximum isometric force was not significantly altered by OM (Fig. 8A). In contrast, 1 and 10 μM OM significantly increased pCa50, indicating that less free Ca2+ was required to produce half-maximal Ca2+ activation (Fig. 8B). These concentrations of OM also slowed koff, the rate of tension recovery following a rapid shortening/re-stretch perturbation (Fig. 8C). These data suggest that OM reduces the
rate at which cross-bridges transition to force-dependent states in a dose-dependent manner.

Discussion

The discovery of drugs that directly interact with myosin to alter the force and velocity properties of cardiac muscle are promising, because they may be able to improve contractile performance without altering calcium homeostasis and myocardial oxygen demand. Our characterization of the motor properties of M2β-S1 suggests there are two kinetic pathways in the presence of OM. The drug can enhance the duty ratio of myosin heads that flux through the conserved ATPase pathway by increasing the period of time they are strongly bound to the actin filament during filament sliding. However, OM also traps some of the myosin heads in a weakly bound state with slow product release. We demonstrate that the main impact of OM

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Average sliding velocity</th>
<th>No. of filaments</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 mM KCl</td>
<td>1783 ± 37</td>
<td>60</td>
</tr>
<tr>
<td>35 mM KCl</td>
<td>1839 ± 35</td>
<td>60</td>
</tr>
<tr>
<td>50 mM KCl</td>
<td>1739 ± 36</td>
<td>60</td>
</tr>
<tr>
<td>75 mM KCl</td>
<td>2074 ± 49</td>
<td>60</td>
</tr>
<tr>
<td>100 mM KCl</td>
<td>1817 ± 22</td>
<td>60</td>
</tr>
<tr>
<td>150 mM KCl</td>
<td>1284 ± 43</td>
<td>30</td>
</tr>
</tbody>
</table>

| OM         |                         |                  |
| 20 mM KCl  | 7.33 ± 0.18             | 60               |
| 35 mM KCl  | 9.39 ± 0.35             | 60               |
| 50 mM KCl  | 9.76 ± 0.25             | 60               |
| 75 mM KCl  | 13.07 ± 0.53            | 60               |
| 100 mM KCl | 14.43 ± 0.20            | 60               |
| 150 mM KCl | 17.17 ± 0.18            | 30               |

FIGURE 4. In vitro motility of M2β-S1 in the presence and absence of OM. The in vitro motility sliding velocity was determined for three different protein preparations in MOPS20 buffer in the presence of 0.1% DMSO (A) and 10 μM OM (B). The M2β-S1 loading density was 0.48 μM. The sliding velocities from all three preparations (150 filaments) were combined to determine the average velocity (nm/s) and standard error for the presence of DMSO (1651 ± 21) or OM (6.87 ± 0.12). C, sliding velocity was determined as a function of OM concentration and fit to Equation 1 to determine EC50. Errors bars represent standard deviation of the mean from two protein preparations (some error bars are smaller than the symbol and therefore are not shown).

FIGURE 5. Impact of ionic strength on the actin-activated ATPase and in vitro motility sliding velocity of M2β-S1. The in vitro motility was measured as in Fig. 4 with the addition of the appropriate amount of KCl in the final activation buffer in the presence of 0.1% DMSO (A) or 10 μM OM (B). The M2β-S1 loading density was 0.48 μM, and an average velocity from 60 filaments analyzed is shown with a red line. C, ATPase activity was examined in the presence of 40 μM actin at different KCl concentrations with and without 10 μM OM. Errors bars represent standard deviation of the mean from two protein preparations (some error bars are smaller than the symbol and therefore are not shown).

FIGURE 6. Density dependence of in vitro motility of M2β-S1 in the presence and absence of OM. We examined the sliding velocity as a function of M2β-S1 concentration loaded into the motility chamber (20 filaments/concentration). The average velocity (relative to the 2.0 μM loading concentration) at each loading concentration is plotted to demonstrate density dependence in low (20 mM KCl) ionic strength (A) and high (100 mM KCl) ionic strength (B). Error bars represent the standard error of the mean (some error bars are smaller than the symbol and therefore are not shown).
on human cardiac muscle mechanics is a shift in calcium sensitivity that is likely caused by the enhanced duty ratio that increases cooperative activation of the thin filament. In addition, OM slows down the kinetics of force development without changing steady-state force at maximum calcium concentrations.

Impact of OM on the Myosin ATPase Cycle in Solution—Our results add to the previous transient kinetic analysis of porcine cardiac heavy meromyosin and bovine cardiac myosin S1 in the presence of OM (6, 24). Similar to the previous findings, we found that when ADP release is measured by mixing a complex of actomyosin-ADP with excess ATP, the determined rate constant is nearly identical in the presence and absence of OM. This method likely monitors the final step of ADP release from actomyosin (K′₅B). We also examined actin-activated product release with sequential mix experiments and provide evidence for two product release pathways. The actin dependence of the rate constants of the fast phase from the sequential mix experiments and the actin filament length is consistent with the increased drag forces that are ionic strength-dependent in the motility assay. Our transient kinetic results are consistent with the 4–5-fold decrease in the maximum steady-state ATPase rate. Further transient kinetic analysis is necessary to directly examine the impact of OM on key steps in the ATPase pathway, including the affinity for actin in the weak binding states and the isomerization between actomyosin-ADP states (K′₅A).

Impact of Omecamtiv Mecarbil on Cardiac Myosin

FIGURE 7. Duty ratio of M2β-S1 in the presence and absence of OM. A, we examined the duty ratio in the presence of DMSO and OM in high ionic strength buffer (100 mM KCl) by examining the sliding velocity as a function of available myosin heads (loading concentration was 0.24 or 0.35 μM). The number of available myosin heads was dependent on the density (determined with NH₄ATPase assays) and the actin filament length. The trend in the data demonstrates a higher duty ratio in the presence of OM. B, velocity as a function of actin filament length (0.24 μM loading concentration) was also plotted, and the data are fit to a hyperbolic function to highlight the relative difference between the two conditions.
the in vitro motility assays (1.17-fold) (42). Therefore, the differences in the velocities observed in this work compared with previous studies could be due to the methods of attaching the myosin to the surface, the length of the lever arm in the constructs examined, the light chain composition, and slight differences in the ionic strength and temperature utilized.

The large decrease in sliding velocity observed in the presence of OM in this study is more pronounced than the previous work with porcine and human cardiac myosin (15–20-fold) (24, 26, 27). One possible explanation for these differences is the higher velocities we observed in the absence of OM allowed for a larger OM-induced decrease to be observed as was found with α-cardiac myosin (26). However, the mechanism of how OM reduces the sliding velocity in the motility assay is still controversial. Our results suggest one major factor that could account for the large decrease in velocity in the presence of OM is the proposed reduction in the ADP isomerization step (K_{5A}), which would increase the time myosin is attached to actin (t_{on}).

If we assume a detachment limited model of sliding velocity \( V = d_{unw} / t_{on} \) (15) and no change in the unitary displacement \( d_{unw} \), then the velocity in the presence of OM is reduced proportionately to \( t_{on} \). Therefore, it is important to examine \( d_{unw} \) and \( t_{on} \) and the rate-limiting step in the M2β-S1 ATPase cycle to further evaluate this argument. Another possibility that has been proposed (24–26) is that OM increases the \( t_{on} \) of force generating cross-bridges by a strain-dependent ADP release mechanism. In this mechanism there is an internal load placed on the actin filament because of myosin heads that have completed their power stroke but are still attached to actin. The attached time of the force generating cross-bridges increases because they have to work against the internal load and adapt by slowing their ADP release rate constant. However, there is currently no direct evidence for changes in strain-dependent ADP release in the presence of OM.

We demonstrate the density dependence of in vitro motility is very unusual in the presence of OM, especially at low ionic strength. The trend of the increase in velocity at lower densities suggests that with fewer heads available there is a reduction in the drag forces that slow the velocity. These drag forces could come from post-power stroke strongly bound heads or weakly bound non-force generating heads. The weakly bound states are strongly affected by increases in ionic strength, which we demonstrate attenuates the OM-induced inhibition of actin sliding. Thus, our results suggest that the inhibition by OM can be attenuated by reducing the number of heads available to interact with the actin filament, which can be altered by changing the ionic strength or the motor density. Our results are consistent with a population of myosin heads trapped in a weak actin binding state that contributes to the drag forces that slow actin filament sliding. However, the sliding velocities observed at the highest ionic strength measured did not return the velocity to the values in the absence of OM. Thus, we propose that both the increase in \( t_{on} \) of force generating heads, by strain-dependent and/or non-strain-dependent mechanisms and drag forces from weakly bound non-force generating heads contribute to the reduced in vitro motility sliding velocity in the presence of OM.

Impact of OM on Cardiac Muscle Mechanics—Studies of the impact of OM on cardiac muscle mechanics are conflicting, but have some common findings. The initial studies fit well into a hypothesis that OM increases the rate of transition into the strong binding states and explains the enhanced force observed in the corresponding muscle fiber studies (6). Further studies on rat myocardium demonstrated an increase in calcium sensitivity with a slowed kinetics of force development and slowed relaxation (22). Recent studies have examined the impact of OM on human myocardium and found that OM increases isometric force at sub-maximal calcium concentrations and slows cross-bridge detachment and recruitment (23). Our study adds to these studies by further examining the impact of OM on human myocardium in a dose-dependent manner. We find an increase in calcium sensitivity with little change in steady-state force at maximum calcium concentrations. In addition, we observe a decrease in the rate of force development. We propose that the rate of force development could be altered by the weakly bound non-force generating cross-bridges or slow detachment of cross-bridges due to a slower ADP isomerization. The ionic strength of the muscle fiber experiments was slightly higher (180 mM) than the highest ionic strength in motility measurements where we still observed a large inhibition of the sliding velocity. Overall the muscle mechanic studies demonstrate that OM may help enhance force at lower calcium concentrations, whereas OM also has the potential to slow force development and reduce shortening velocity.
The results from clinical trials demonstrate that OM can improve systolic ejection time and stroke volume (18). However, end diastolic volume was reduced, which is in agreement with an impact on slowed relaxation kinetics. In addition, some patients experienced ischemia at higher doses. A larger phase II clinical trial found OM was well tolerated and confirmed previous reports of increases in systolic ejection time, although there was no improvement in the primary end point of dyspnea (20). Another study suggests OM causes an increase in oxygen consumption, which could impact bioenergetics in long term treatment regimens (43). Overall, it appears that dosing could be critical to receive the maximum benefits of the OM-induced increase in force at sub maximal calcium without impacting the rate of force development and shortening velocity.

Summary—We have performed a thorough analysis of human M2β-S1 in the presence and absence of OM using both in vitro motility and solution ATPase studies. We complement this work with an investigation of the impact of OM on human cardiac muscle mechanics. Our results support a model that suggests OM slows ATPase cycle kinetics by slowing the transition between actomyosin-ADP states which results in an increase in duty ratio. OM also results in a population of cross-bridges trapped in a weak actin binding state with slow product release. The enhanced duty ratio increases the time period that myosin heads are attached to the thin filament in cardiac muscle which cooperatively activates the thin filament, enhances calcium sensitivity, and increases force at low calcium without changing steady-state force at maximum calcium. The negative impact of OM appears to be that it slows force development and could slow shortening velocity and may cause ischemia at high doses. Despite these potential drawbacks, an appropriate dose may provide a critical boost to contractile force in systolic heart failure patients. In addition, OM is an interesting proof of concept drug that may pave the way for future treatments that directly interact with contractile proteins to enhance the force and velocity properties of cardiac muscle.

Experimental Procedures

Reagents—ATP and ADP were prepared from powder (44). Omecamtiv mecarbil (CK-1827452) was purchased from Selleck Chemicals or AdooQ Bioscience. Omecamtiv mecarbil was dissolved in DMSO at a concentration of 10 mM. All solution experiments were performed in MOPS20 buffer (10 mM MOPS, pH 7.0, 20 mM KCl, 1 mM EGTA, 1 mM MgCl2, 1 mM DTT) with the addition of appropriate KCl concentrations as indicated.

Construction of Expression Plasmids—The human cardiac myosin cDNA (AAA5187.1) was purchased from Thermo Fisher Scientific. PCR amplification was used to subclone the M2β-S1 construct (amino acids 1–843) into the psuttle vector (a gift from Dr. Don Winkelmann). M2β-S1 was engineered to contain an N-terminal FLAG tag sequence and C-terminal Avi tag sequence.

Recombinant Adenovirus-based Expression and Purification of M2β-S1 in C2C12 Cells—The production of high titer adenovirus DNA was digested with Pac1 and transfected into Ad293 cells to allow for virus packaging and amplification. The Ad293 cells were grown in DMEM supplemented with 10% fetal bovine serum. The large scale virus preparation was performed by infecting 60 plates (145 mm diameter). The virus was harvested with freeze-thaw cycles followed by CsCl density sedimentation. The final virus titers were typically 1010 to 1011 pfu/ml.

C2C12 cells grown to 90% confluence in DMEM supplemented with 10% fetal bovine serum (typically 20–30 145-mm diameter plates) were differentiated by changing the media to DMEM supplemented with 10% horse serum and 1% fetal bovine serum. The C2C12 cells were infected with recombinant adenovirus (5 × 108 pfu/ml) diluted into differentiation media. The media were changed after 2 days, and cells were harvested on day 7. The cells were lysed with a 50-ml Dounce in lysis buffer (50 mM Tris, pH 7.0, 200 mM KCl, 2 mM ATP, 1 mM AMP, 0.5% Tween 20, 0.01 mg/ml aprotinin, 0.01 mg/ml leupeptin, 1 mM PMSF) and spun two times for 15 min at 25,000 rpm in a Ti50 rotor at 4 °C. The supernatant was added to a 1-mL anti-FLAG M2 resin column, washed with wash buffer (10 mM Tris, pH 7.5, 200 mM KCl, 1 mM EGTA, 1 mM EDTA, 2 mM MgCl2, 2 mM ATP, 1 mM DTT, 0.01 mg/ml aprotinin, 0.01 mg/ml leupeptin, 1 mM PMSF), and eluted with wash buffer containing FLAG peptide (0.167 mg/ml). The eluted M2β-S1 was subsequently precipitated with ammonium sulfate and dialyzed into MOPS20 buffer overnight at 4 °C. M2β-S1 was biotinylated in vitro motility studies by incubating M2β-S1 with BirA (10 μg/ml) for 1 h at 25–30 °C, and subsequently precipitated with ammonium sulfate and dialyzed into MOPS20 buffer overnight at 4 °C (46).

M2β-S1 purity was assessed by Coomassie-stained SDS-polyacrylamide gels, and protein concentration was determined by Bradford assay using BSA as a standard. Similar results were obtained by measuring the absorbance and using the predicted extinction coefficient (ε290 = 1.38 × 104 M⁻¹ cm⁻¹). Actin was purified from rabbit skeletal muscle using an acetone powder method (47). The actin concentration was determined by absorbance at 290 nm (ε290 = 2.66 × 104 M⁻¹ cm⁻¹). A molar equivalent of phalloidin was added to stabilize F-actin.

Mass Spectrometry—Expression of M2β-S1 light chain isoforms was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The myosin light chains associated with the M2β-S1 were separated on SDS-polyacrylamide gels and stained by Coomassie. The two resultant low molecular mass bands (~22 and 19 kDa) were excised from the gel, destained with 50% acetonitrile, and digested with 1 μg of trypsin (Promega) in 50 mM ammonium bicarbonate as described (48). The resultant peptides were reconstructed in 0.05% heptafluorobutyric acid and separated on an Acquity UPLC HSS T3 column (100 Å, 1.8 μm, 1 × 150 mm) (Waters) attached to a Dionex UltiMate 3000 HPLC (Dionex). The HPLC effluent was directly injected into a Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer through an electrospray ionization source (Thermo Fisher Scientific). Data were collected in data-dependent MS/MS mode with the top five most abundant ions.
Impact of Omecamtiv Mecarbil on Cardiac Myosin

being selected for fragmentation. Peptides were identified from the resultant MS/MS spectra by searching against a mouse database (downloaded from UniProt 2/15) using SEQUEST for running the Proteome Discoverer 2.1 software (Thermo Fisher Scientific). Peptide oxidation was accounted for by addition of 15.99 and 31.99 Da to each methionine residue. All MS/MS fragmentation spectra were manually confirmed. The area under each deisotoped LC peak was determined using Proteome Discoverer 2.1 (Thermo Fisher Scientific).

Steady-state ATPase Activity—Steady-state ATP hydrolysis by M2β-S1 (100 nM) in the absence and presence of actin (0–60 μM) was examined by using the NADH-linked assay (49–52) with a final MgATP concentration of 1 mM. The assay was performed in an Applied Photophysics stopped-flow apparatus (Surrey, UK) in which the NADH absorbance at 340 nm was monitored continuously for 200 s. The ATPase rate at each actin concentration was determined, and the Michaelis-Menten equation (57)

\[ V_e + (k_{cat} \text{[actin]}(K_{ATPase} + \text{[actin]})) \]

was used to determine $k_{cat}$ and $K_{ATPase}$, where $V_e$ is the ATPase rate in the absence of actin; $k_{cat}$ is the maximal ATPase rate, and $K_{ATPase}$ is the actin concentration at which the ATPase activity is half-maximal. The data at each actin concentration represents an average of 2–3 protein preparations.

Actin Co-sedimentation Assay—The steady-state actin affinity of M2β-S1 in the presence of ATP was measured using an actin co-sedimentation assay. M2β-S1 (0.2 μM) was equilibrated with various actin concentrations (0–60 μM) in MOPS20 buffer containing the ATP regeneration system (20 units ml$^{-1}$ pyruvate kinase and 2.5 mM phosphoenolpyruvate). We added 1 mM ATP and immediately centrifuged the samples for 8 min at 25 °C (TLA.120.1 rotor at 120,000 rpm). The supernatant and pellet were examined by SDS-PAGE followed by Western blotting, and the biotinylated M2β-S1 was detected using a streptavidin–alkaline phosphatase conjugate. The intensity of the M2β-S1 bands was examined using ImageJ, and the fraction bound was determined using the equation pellet/(supernatant + pellet). The plot of fraction bound as a function of actin concentration was fit to a hyperbolic function to determine the steady-state actin affinity ($K_{actin}$).

Transient Kinetic Studies—The stopped-flow apparatus equipped with an excitation monochrometer (2-nm band pass filter) and appropriate emission filters was used to examine key steps in the actomyosin ATPase cycle of M2β-S1. The mttlabeled nucleotides were excited at 290 nm, and the emission was measured with a 395-nm long pass filter. The fluorescence transients were fitted using custom software provided with the instrument or with GraphPad Prism, and errors are reported as standard errors of the fit. All concentrations listed are final unless otherwise noted.

In Vitro Motility Assay—The actin filament sliding assay was performed as described previously (53) except for the method of adhering the myosin to the surface. Microscope coverglasses were coated with 1% nitrocellulose in amyl acetate (Ladd Research). The surface was coated with streptavidin (0.1 mg/ml) and blocked with BSA (1 mg/ml) before the addition of biotinylated M2β-S1 (loading concentration, amount added to the flow cell, was varied between 0.24 and 2.0 μM). Unlabeled actin (2 μM) followed by an ATP (2 mM) wash was used to prevent interactions with dead heads. Actin labeled with either rhodamine phallolidan (DS Red filter; excitation/emission: 545/620 nm) or Alexa (GFP filter; excitation/emission, 500/535 nm) was visualized by fluorescence microscopy. An activation buffer with an appropriate concentration of DMSO or OM was added to the flow cell to initiate motility. Activation buffer contained the following: MOPS20 buffer, 0.35% methylcellulose, 2.5 mM phosphoenolpyruvate, 20 units·ml$^{-1}$ pyruvate kinase, 0.1 mg·ml$^{-1}$ glucose oxidase, 5 mg·ml$^{-1}$ glucose, 0.018 mg·ml$^{-1}$ catalase, and 2 mM ATP. The slide was promptly viewed using a NIKON TE2000 microscope equipped with a ×60/1.4NA phase objective and a Perfect Focus System. Images were acquired every second for 3 min or every 15 s for 10 min in the absence and presence of OM, respectively, using a shutter-controlled CoolSnap HQ2-cooled CCD digital camera (Photometrics) binned 2 × 2. Temperature was maintained at 26 ± 1 °C and monitored using a thermocouple meter (Stable Systems International). Image stacks were transferred to ImageJ for analysis via MTrack (54) and corrected for drift using StackReg. The average velocity was determined by tracking actin filaments manually for each condition (e.g., the path of each filament was determined by tracking the filament on a frame-by-frame basis, which allowed determination of average velocity). The actin filament lengths were measured using the length tool in ImageJ.

The number of myosin heads on the motility surface was measured using an NH$\text{4}$-ATPase assay (34, 55). We evaluated the number of moles of phosphate produced in a motility flow cell chamber and compared that with a standard curve of moles of phosphate produced per concentration of M2β-S1. To determine the number of heads available per μm of actin filaments, we assumed that M2β-S1 could interact with a 20-nm band of the actin filament (10 nm of either side of the filament). The plot of the relative velocity as a function of myosin heads available (33, 34) was utilized to demonstrate the relative difference in duty ratio in the presence of OM.

The plots of the relative ATPase and motility as a function of OM concentration were fit to Equation 1,

\[ y = \text{Bottom} + (\text{Top} - \text{Bottom})/(1 + 10^{-(x - \log IC_{50})}) \]

(Eq. 1)

where $x$ = OM concentration, and $y$ = relative ATPase activity or sliding velocity, and Bottom and Top are the associated plateaus.

Human Tissue—The cardiac samples used in this study were obtained from patients at the University of Kentucky who had end-stage heart failure using the procurement system described by Blair et al. (56). Briefly, through-wall sections of the distal anterior region of the left ventricle were obtained from hearts that had been explanted during a cardiac transplant. Samples weighing ~500 mg were dissected from these sections, placed in 2-ml cryogenic vials, and snap-frozen in liquid nitrogen. The vials were subsequently stored in the vapor phase of liquid nitrogen at −150 °C until use. The experiments described in this study used specimens isolated from the sub-endocardial region of eight patients. All procedures were approved by the
Impact of Omecamtiv Mecarbil on Cardiac Myosin

Acknowledgment—We thank Dr. Don Winkelmann, Rutgers University, for sharing his expertise on the adenovirus-based \text{C}3\text{C}12 expression system.

References

Impact of Omecamtiv Mecarbil on Cardiac Myosin


